Skip to content

Comment on BioNTech CEO applies Covid-19 vaccine's mRNA tech to multiple sclerosisparent

Comments

They were working on applying mRNA technology to other diseases, including (and in particular) cancer, well before the pandemic. While it is true that they have received significant funding this year, they had a $7.6B market cap on Dec 31, 2019 and were already conducting several clinical studies for mRNA-based medicine [1].

[1] https://web.archive.org/web/20200128054759/https://biontech....

Smaller companies here in the bay area as well, see: Rejuvenation Tech.

Moderna is too.

AboutSource Built by g1lg1l

Hackerly is an independent reader for Hacker News, built on the public HN API. Not affiliated with Y Combinator.